Idexx Laboratories Inc - IDXX STOCK NEWS

IDEXX Laboratories (NASDAQ: IDXX) announced new testing services to enhance veterinary care, effective September 2022. Key additions include Fecal Dx antigen testing for flea tapeworm detection, FGF-23 kidney biomarker testing for managing chronic kidney disease in cats, and next-day PCR Direct testing services. These innovations aim to improve diagnostics, enable earlier intervention in critical cases, and support veterinarians in their treatment plans, thereby advancing pet healthcare standards.

IDEXX Laboratories, a leader in veterinary diagnostics, will participate in the Stifel Jaws & Paws Conference on June 1, 2022, at 1:50 pm (EDT). President Jay Mazelsky and CFO Brian McKeon will join a fireside chat. A live audio webcast can be accessed via IDEXX's website. Additionally, IDEXX will host its 2022 Investor Day on August 11, 2022, at its headquarters in Westbrook, Maine, from 8:00 am to 12:00 pm (EDT). More details will follow closer to the event date.

IDEXX Laboratories reported an 8% revenue growth for Q1 2022, driven by CAG Diagnostics recurring revenue growth of 8% reported and 9% organic. Strong demand resulted in a 19% reported and 22% organic growth in CAG Diagnostics capital instrument revenue. However, EPS declined by 3% as reported, while it increased 3% on a comparable basis. The company adjusted its full-year guidance, anticipating 5.5%-8% reported growth, impacted by reduced veterinary clinical visits and foreign exchange rates. Key financial metrics include an updated EPS outlook of $8.11 - $8.35.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced the release of its 2022 first quarter financial results, scheduled for May 4, 2022, before market opening. An analyst conference call will follow at 8:30 a.m. ET, accessible via a live webcast on the IDEXX website. The archived webcast will be available after 1:00 p.m. ET and will remain for one year. IDEXX, a leader in veterinary diagnostics and healthcare innovation, employs over 10,000 people and serves customers in over 175 countries worldwide.

IDEXX Laboratories (NASDAQ: IDXX), a leader in veterinary diagnostics, will participate in two upcoming conferences. On February 24 at 9:55 am EST, executives Tina Hunt and Brian McKeon will engage in a virtual fireside chat at the BofA Securities Animal Health Summit. Following that, on March 7 at 11:00 am EST, CEO Jay Mazelsky will present at the 43rd Annual Raymond James Institutional Investors Conference. Live webcasts and archived editions of the presentations will be accessible on the IDEXX website.

IDEXX Laboratories reported an 11% increase in fourth quarter revenue, totaling $801 million, primarily driven by a 13% growth in CAG Diagnostics recurring revenue. Full-year revenue reached $3,215 million, up 19%, with an EPS of $8.60, a 28% increase. The company anticipates 2022 revenue of $3.5-$3.565 billion and EPS of $9.27-$9.59. Despite strong overall performance, LPD segment revenue declined 20% due to prior year high testing demand. The company remains positive about growth in companion animal healthcare.

PetDx has announced a collaboration with IDEXX Laboratories to enhance access to its liquid biopsy test for canine cancer, OncoK9. This test, which allows for noninvasive cancer detection through a simple blood draw, will be available to veterinary customers in the U.S. and Canada by the end of January 2022. OncoK9 utilizes advanced genomic analysis and sequencing technology, showing promising results in clinical studies. With an estimated six million new canine cancer diagnoses annually, this collaboration aims to improve diagnostics and care for dogs suffering from cancer.

IDEXX Laboratories (NASDAQ: IDXX) announced enhancements to its products and services aimed at improving veterinary practices' efficiency amidst rising patient volumes. Key enhancements include clinical decision support for the IDEXX 4Dx® Plus Test, improvements to the VetConnect® PLUS Mobile App, advanced software for the SediVue Dx® Urine Sediment Analyzer, and a new Catalyst® SDMA Test to streamline workflows. These innovations are designed to aid veterinarians in making quicker, confident clinical decisions, reflecting IDEXX's commitment to supporting the growing demands of veterinary professionals.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the expansion of its reference laboratory tests to improve cancer diagnosis and treatment for veterinarians. This new offering includes a liquid biopsy test using DNA sequencing for common canine cancers, a diagnostic panel for identifying genetic mutations, and innovative diagnostic profiles for therapy management. With around 6 million new cancer diagnoses annually in dogs and cats in the U.S., IDEXX aims to support veterinarians in managing complex cancer cases more effectively.